Summit Therapeutics Inc. filed a letter providing unaudited balance of cash, cash equivalents and amounts included in escrow as of December 31, 2022, which was no less than $648 million, subject to completion of financial closing procedures. The company also announced the approval of amendments to increase the number of authorized shares of common stock and to effect a reverse stock split at a Special Meeting of Stockholders. Additionally, the company disclosed its participation in the 41st Annual J.P Morgan Healthcare Conference and provided presentation slides.